Immunogen (IMGN) Reports Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab
ImmunoGen, Inc. (NASDAQ: IMGN) today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)